Dermapharm Announces Dividend for 2024
Dermapharm Holding SE recently announced a dividend of 0.90 euros per share for the fiscal year 2024, matching the expectations of analysts from mwb research. A total of 48.5 million euros will be distributed to shareholders, representing a payout ratio of 43% of adjusted earnings.
General Meeting and Decisions
The decision on the dividend was made at the annual general meeting on June 26, 2025, in Grünwald, where 14.6% of shareholders were present, supporting all proposals from the company’s management. Analysts positively evaluated this decision and reaffirmed their buy recommendation with a price target of 45 euros.
Financial Forecasts for 2025
For the year 2025, Dermapharm plans to achieve revenue growth between 1.16 and 1.2 billion euros and an adjusted EBITDA of 322 to 332 million euros. These goals are to be reached through the expansion of the branded pharmaceuticals portfolio and sustainable supply chain development. Experts expect the dividend for 2025 to increase to 0.98 euros.
Strategic Expansion and Partnerships
A key part of the growth strategy is to strengthen international presence, including through partnerships such as the one with the French company Arkopharma. Furthermore, Dermapharm plans to launch new products to strategically expand its portfolio and enhance efficiency.
Future Outlook
Analysts’ forecasts suggest that revenue will rise to 1.222 billion euros by 2026. Dermapharm thus pursues clear goals regarding growth and continuously strengthens its market position.